Neurology and Neurosurgery - Global Neurology Academy

33-48 of 481

Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Strategies to Safeguard Brain Health in MS
Strategies to Safeguard Brain Health in MS
NeuroFrontiers
Strategies to Safeguard Brain Health in MS
Christopher Lock, MD
- Christopher Lock, MD
Rethinking Progression in Multiple Sclerosis
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
Charles Turck, PharmD, BCPS, BCCCP; Christopher Lock, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Lock, MD
The Burden of Cognitive Dysfunction in Multiple Sclerosis
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiers
The Burden of Cognitive Dysfunction in Multiple Sclerosis
Christopher Lock, MD
- Christopher Lock, MD
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
- Ryan Quigley
Who’s Missing from Multiple Sclerosis Research?
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
Ashley Baker, MSN, PMHNP; Ruth Ann Marrie, MD, PhD
- Ashley Baker, MSN, PMHNP
- Ruth Ann Marrie, MD, PhD
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Raphael Schneider, MD, PhD, FRCPC, CIP
- Raphael Schneider, MD, PhD, FRCPC, CIP
Multiple Sclerosis Without Borders: Taking a Global View
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
Andrew Wilner, MD, FACP, FAAN; Victor Rivera, MD
- Andrew Wilner, MD, FACP, FAAN
- Victor Rivera, MD
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Adil Harroud, MD; Dylan Hamitouche
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley
Understanding Accelerated Biological Aging in Pediatric MS
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
Jennifer Yang, MD
- Jennifer Yang, MD
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Ashkan Shoamanesh, MD
- Ashkan Shoamanesh, MD
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Mike Sharma, MD, MSc, FRCPC
- Mike Sharma, MD, MSc, FRCPC
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Alexandria May, PharmD, BCPS; Apurva Bhatt, MD
- Alexandria May, PharmD, BCPS
- Apurva Bhatt, MD

3/8